跳至主要内容
临床试验/NCT05112276
NCT05112276已完成不适用

Food4GutMarKIT - Evaluation of a Tailored Personalized Food Concept for a Healthy Gut Microbiota and Validation of Biomarkers for Monitoring of Its Effects

Chalmers University of Technology1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2021年10月27日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
40
试验地点
1
主要终点
Gut microbiome

研究概览

简要总结

The overall aim in this "proof-of-concept" study is to evaluate if a diet concept, based on foods that have individually been reported to beneficially affect gut microbiota in fact has an effect on gut microbiota composition and activity among healthy and obese subjects and whether the effects are associated with altered cardiometabolic risk factors. The aim is further to investigate if such alterations are reflected in changes of the fecal and plasma metabolome. In total, 40 men and women, who meet all the inclusion criteria and none of the exclusion criteria will be invited to participate in the study. The participants will follow an intervention diet for 6 weeks and a control diet for 6 weeks, with a 6-week wash-out period in between and will be randomized to either begin with the intervention diet or the control diet.

The study will be running over 18 weeks (including a 6-week wash-out period) and it will include 9 visits at the clinic.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Other
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Men and women
  • Age 18 - 70 years
  • BMI 18,5-25 for normal weighed and BMI 25-39 for overweighed/obese
  • Hb ≥ 120g/L
  • Serum TSH <4,0 mIU/L
  • Signed informed consent
  • Among the overweighed, they need to have waist circumference > 102 cm/88 cm for men and women respectively. All overweighed participants must have one of the following risk factors for cardiovascular decease, whereas the normal weighed could have or not elevated risk factors:
  • LDL ≥ 3,0 mmol/L
  • HDL ≤1.04 mmol/L
  • Total cholesterol ≥ 5.0 mmol/L
  • Triglycerider ≥1.69 mmol/L
  • Blood pressure ≥130/85 mmHg
  • Fasting glucose ≥6.1 mmol/L.

排除标准

  • Blood donation or participation in a clinical study with blood sampling within 30 days prior to screening visit and throughout the study.
  • Following any weight reduction program or having followed one during the last 6 months
  • Food allergies or intolerances
  • Vegetarian or other diet restrictions (due to the standardized meal plan)
  • History of stomach or gastrointestinal conditions (Inflammatory bowel disease, Crohn's disease, malabsorption, colostomy, bowel resection, gastric bypass surgery etc.)
  • Previous major gastrointestinal surgery
  • Pregnant or lactating or wish to become pregnant during the period of the study.
  • Unable to understand written and spoken Swedish
  • Lack of suitability for participation in the trial, for any reason, as judged by the medical doctor or PI.
  • Pharmacological medication with drugs known to affect the microbiota, e.g. antibiotics, within 6 months prior to baseline.
  • Intake of probiotics within 6 months prior to baseline.
  • Have type I diabetes
  • Receiving pharmacological treatment for type II diabetes (treatments based on life style interventions are acceptable, as long as it is compatible with the study protocol)
  • Using nicotine products on a daily basis (including chewing gum, patches, snus etc.)
  • History of heart failure or heart attack (TIA) within 1 year prior to screening
  • Thyroid disorder

结局指标

主要结局

Gut microbiome

时间窗: 6 weeks, 18 weeks

Fecal samples will analyzed for composition of the gut microbiome. Change in gut microbiota OTUs between baseline and 6 and 18 weeks of intervention or control.

次要结局

  • Blood pressure(3 weeks, 6 weeks, 12 weeks and 18 weeks)
  • Triglycerides(3 weeks, 6 weeks, 12 weeks and 18 weeks)
  • Low-density lipid protein(3 weeks, 6 weeks, 12 weeks and 18 weeks)
  • High-density lipid protein(3 weeks, 6 weeks, 12 weeks and 18 weeks)
  • C-reactive protein(3 weeks, 6 weeks, 12 weeks and 18 weeks)
  • Cholesterol(3 weeks, 6 weeks, 12 weeks and 18 weeks)
  • Fasting glucose(3 weeks, 6 weeks, 12 weeks and 18 weeks)

研究者

发起方
Chalmers University of Technology
申办方类型
Other
责任方
Principal Investigator
主要研究者

Rikard Landberg

Professor

Chalmers University of Technology

研究点 (1)

Loading locations...

相似试验